



7-1-2022

Serum Level Of Interleukin-23 in patients with Juvenile Idiopathic Arthritis and correlation to Disease Activity

hatem abdelkafy

Rheumatology department , Al Azhar students hospital , Cairo , Egypt, hatemabdelkafy@gmail.com

khaled Amer

Rheumatology department, faculty of medicine , AL Azhar university, khaled-moez@yahoo.com

Kolthoum Abdel Hamid

Rheumatology department, faculty of medicine , AL Azhar UNIVERSITY, kolthoumabdelhamid@gmail.com

Mahmoud Hashish

Clinical pathology department, faculty of medicine, AL azhar university, mahmoudhashish@gmail.com

Follow this and additional works at: <https://aimj.researchcommons.org/journal>



Part of the [Medical Sciences Commons](#), [Obstetrics and Gynecology Commons](#), and the [Surgery Commons](#)

How to Cite This Article

abdelkafy, hatem; Amer, khaled; Abdel Hamid, Kolthoum; and Hashish, Mahmoud (2022) "Serum Level Of Interleukin-23 in patients with Juvenile Idiopathic Arthritis and correlation to Disease Activity," *Al-Azhar International Medical Journal*: Vol. 3: Iss. 7, Article 6.

DOI: <https://doi.org/10.21608/aimj.2022.113292.1811>

This Original Article is brought to you for free and open access by Al-Azhar International Medical Journal. It has been accepted for inclusion in Al-Azhar International Medical Journal by an authorized editor of Al-Azhar International Medical Journal. For more information, please contact dryasserhelmy@gmail.com.

Serum level of Interleukin 23 in Patients with Juvenile Idiopathic Arthritis

Hatem Ahmed Abdelkafy^{1*} MSc., Kolthoum Mohamed Abdel Hamid¹ MD., Khaled Mohammed Amer¹ MD. and Mahmoud Abdellatif Hashish² MD.

* Corresponding Author:

Hatem Ahmed Abdelkafy
hatemabdelkafy@gmail.com

Received for publication January 24, 2022; Accepted July 22, 2022;
Published online July 22, 2022.

doi: 10.21608/aimj.2022.113292.1811

Citation: Hatem A. , Kolthoum M. , Khaled M. et al. Serum level of Interleukin 23 in Patients with Juvenile Idiopathic Arthritis. AIMJ. 2022; Vol.3-Issue7 : 26-29.

¹Department of Rheumatology and rehabilitation, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

²Department of Clinical pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

ABSTRACT

Background: Juvenile idiopathic arthritis is considered to be the commonest rheumatic disease in children, IL-23 has a major role in promoting inflammation in target organs.

Aim of the work: To assess the serum interleukin-23 level in Juvenile Idiopathic Arthritis and its correlation to the disease activity.

Patients and Methods: Fifty JIA patients fulfilling the ILAR classification criteria were included in a case-control study and classified into three groups: Polyarticular Rheumatoid factor positive JIA (n = 15), Polyarticular Rheumatoid factor Negative JIA (n = 17), Oligoarticular JIA (n = 18), and eighteen healthy children as a control group. The juvenile arthritis disease activity score (JADAS 71), CHAQ (Childhood Health Assessment Questionnaire), serum IL 23 level, ESR, CRP, ANA and RF were measured for all cases.

Result: Mean age for Polyarticular Rheumatoid factor positive JIA (10.47±4.12), Polyarticular Rheumatoid factor negative JIA (9.19±3.33), Oligoarticular JIA(9.61±3.5) and for healthy children (8.67±3.47). Highest serum IL-23 levels were in Polyarticular Rheumatoid factor negative (median 34.31 ng/ml) followed Polyarticular Rheumatoid factor positive JIA and Oligoarticular JIA (median 22.03 ng/ml) and (median 11.87 ng/ml) respectively. The least values were found in the sera of normal children (median 2.75ng/ml). A significant positive correlation between IL-23 levels and JADAS 71 & CHAQ score most pronounced in the Polyarticular Rheumatoid positive JIA patients.

Conclusion: JIA patients had significantly more serum IL-23 than healthy individuals, and positively correlated with disease activity indices.

Keywords: Juvenile idiopathic arthritis; Activity; IL-23; JADAS-7; CHAQ.

Disclosure: The authors have no financial interest to declare in relation to the content of this article. The Article Processing Charge was paid for by the authors.

Authorship: All authors have a substantial contribution to the article

Copyright The Authors published by Al-Azhar University, Faculty of Medicine, Cairo, Egypt. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles under the following conditions: Creative Commons Attribution-Share Alike 4.0 International Public License (CC BY-SA 4.0).

INTRODUCTION

Juvenile Idiopathic Arthritis (JIA) is the commonest rheumatic disease that affects children.¹

JIA is diagnosed in children younger than 16 years with arthritis which persist for more than 6 weeks with no other underlying cause.²

JIA is accounted as a significant cause of acquired impairment and disabilities in children.³

The prevalence of JIA in Egypt is estimated to be 3.43 - 20 cases in every 100,000 occupant and worldwide is 1-3 per 1,000 children.⁴

Interleukin-23 as one of the IL-12 cytokine family with pro-inflammatory properties. it is responsible for various autoimmune responses in JIA as it promotes the expansion of the T helper type 17.⁵

IL-23 has a crucial role in the progression and severity of JIA.⁶

This work aimed to evaluate serum IL 23 as a novel biomarker for JIA diseases activity.

PATIENTS AND METHODS

A case-control study included Fifty JIA patients fulfilling the ILAR classification criteria were classified into three groups: Group A: Polyarticular Rheumatoid factor positive JIA (n = 15), Group B: Polyarticular Rheumatoid factor Negative JIA (n = 17), Group C: Oligoarticular JIA (n = 18), and eighteen healthy children as a control group. They were selected from AL Al-Azhar university hospitals Rheumatology Departments, between March 2017 and June 2020. Other reasons of childhood arthritis were excluded, such as Infection, malignancy,

rheumatic fever with obtained informed consent from all participants.

All participants were subjected to Disease activity assessment by Juvenile arthritis disease activity score (JADAS 71) ⁷, CHAQ (Childhood Health Assessment Questionnaire) ⁸. As well as , laboratory assessment including C - reactive protein (CRP), Erythrocyte sedimentation rate (ESR), complete blood count (CBC), RF, ANA and Serum IL-23 by ELISA.

Statistical analysis was done as follows; the statistical package for the social sciences, version 23.0, has been employed to collect, code, revise, and enter data (SPSS Inc., Chicago, Illinois, USA). The quantitative data has been presented as mean, standard deviations when the parametric distribution is normal. In contrast, non-normally distributed variables (non-parametric data) have been shown to have a median with an inter-quartile range (IQR). Numbers and percentages have also been employed to represent qualitative variables. Data was examined

for normalcy employing the Kolmogorov-Smirnov and Shapiro-Wilk tests, as well as the relationship between qualitative variables employing the Chi-square test (X²). ANOVA or Kruskal-Wallis, Spearman's correlation to compare differences between quantitatively independent multiple groups. The margin of error acceptable was 5%, with a confidence interval of 95%. As a result, the significance of the p-value was determined as follows: p-values > 0.05 indicate non-significant (NS), p-values < 0.05 indicate significance (S), and p-values < 0.01 indicate highly significant (HS).

RESULTS

The mean age of JIA patients included were (9.40±10.1) and for healthy children (8.6±3.4).

The serum IL-23 receiver operating curve (ROC) has been discovered at levels greater than ≥15.00 pg/ml for JIA subgroups with 80 % sensitivity, 91.7% specificity, 92.3% positive predictive value (PPV), and 78.6 % negative predictive value (NPV) (Table 1).

Groups	Cut-off	Sen.	Spe.	PPV	NPV	AUC [95% C.I.]	p-value
JIA PATIENTS	≥15.00 pg/ml	80%	91.7%	92.3%	78.6%	0.944 [0.782-0.993]	<0.001

Table 1: The IL 23 cutoff value, sensitivity, and specificity.

There was a highly statistically significant difference between JIA subgroups according to serum IL-23 with p-value (p<0.001). The highest value was found in the group A and group B (29.77±13.41 & 34.31±9.14),

followed by Group C (11.87±5.80), while the lowest value was found in control group (2.75±2.16) (Table 2) (Figure 1).

Serum IL-23	Group A (n=15)	Group B (n=17)	Group C (n=18)	Control group (n=18)	Test value	p-value
Mean±SD	29.77±13.41#	34.31±9.14#	11.87±5.80#	2.75±2.16#	38.997	<0.001**
Range	2-40	8.9-42	1-19	0-16		

Table 2: Comparison between study groups according to serum IL-23 in pg/ml.




Fig. 1: Bar chart between groups according to serum IL-23.

A highly statistically significant positive correlation between serum IL-23 with JADAS 71 (figure 2) & CHAQ in group A and significant positive correlation in group B Polyarticular JIA.

In group C Oligoarticular JIA we discovered a positive correlation only with the JADAS71 (table 3).

JIA Subgroups	Serum IL-23	
	R	p-value
Group A	CHAQ	0.825 <0.001**
	JADAS 71	0.881 <0.001**
Group B	CHAQ	0.519 0.033*
	JADAS71	0.567 0.018*
Group C	CHAQ	0.356 0.147
	JADAS71	0.480 0.044

Table 3: correlation between IL-23 and JADAS 71 and CHAQ in JIA subgroups.




Fig. 2: Statistically significant positive correlation between serum IL-23 and JADAS 71 in group A.

DISCUSSION

JIA is a group of inflammatory arthritis affecting children aged less than 16 years.⁹

Commencement of the JIA pathological process incorporates dysregulated activation of T-cells, B-cells, dendritic cells, natural killer cells, neutrophils and macrophages which produce cytokines leading to joint affection and other systemic manifestations. The studied cytokines which lead to progression of JIA and various autoimmune diseases have recently included IL-23.¹⁰

The current study goal was evaluation of the level of IL-23 in JIA patients so that it may be used as a novel marker for activity as well as reinforcing the trial of IL-23 antagonists as a potential therapeutic option in controlling the refractory JIA disease activity.

Our study showed significant increased levels of serum IL-23 in JIA subgroups compared to healthy controls. There was a highly statistically significant difference between groups according to serum IL-23 level with p-value ($p < 0.001$). The highest value was found in the group A and group B (29.77 ± 13.41 & 34.31 ± 9.14 pg/ml) respectively, followed by Group C (11.87 ± 5.80 pg/ml), while the lowest value was found in the control group (2.75 ± 2.16 pg/ml).

This is in agreement with Prahalad et al.,¹⁰ who discovered the presence of significant difference in the IL-23 levels between JIA patients and controls, in which the highest level was in the Polyarticular JIA with average level (25.7 pg/ml).

This is in line with Tzimouli et al.,⁶ who measured IL-17, IL-23 in synovial fluid and serum of 69 JIA patients and found that serum and synovial fluid IL-23 was significantly higher in JIA patients compared to control.

Yet Szymańska-Kałuża et al.,¹¹ reported the presence of higher IL-23 level in patients with

persistent oligoarthritis when comparing them to normal individuals.

We discovered a highly statistically significant positive correlation between the IL-23 in the serum of JIA subgroups and JADAS 71.

So far, no studies have looked into the association between IL-23 levels with JADAS71 & CHAQ in JIA.

So, the IL-23 is predicted to have a potential role as a biomarker to the JIA disease activity.

CONCLUSION

Serum interleukin 23 is elevated in JIA patients with higher prevalence in polyarticular JIA followed by Oligoarticular JIA. In addition, it was found to be correlated with the disease activity. IL-23 may be considered as a potential biomarker for JIA disease activity. As well as, children with refractory JIA might get benefit of IL-23 inhibitors.

Conflict of interest : none

REFERENCES

1. Albokhari S, Muzaffer M. Anemia in Juvenile Idiopathic Arthritis (JIA) and Other Pediatric Rheumatologic Diseases: A Retrospective Study. *Open Journal of Rheumatology and Autoimmune Diseases*. 2021;11(04):188-202. doi:10.4236/ojra.2021.114019
2. Barut K, Adrovic A, Şahin S, Kasapoğlu Ö. Juvenile Idiopathic Arthritis. *Balkan Med J*. 2017;34(2):90-101. doi:10.4274/balkanmedj.2017.0111
3. Basra HAS, Humphries PD. Juvenile idiopathic arthritis: what is the utility of ultrasound?. *Br J Radiol*. 2017; 90 (1073): 20160920. doi:10.1259/bjr.20160920
4. Abou El-Soud A, El-Najjar A, El-Shahawy E et al. Prevalence of juvenile idiopathic arthritis in Sharkia Governorate, Egypt: epidemiological study. *Rheumatol Int*. 2013; 33 (9): 2315-22. doi:10.1007/s00296-013-2707-2
5. Tang C, Chen S, Qian H, Huang W. Interleukin-23: as a drug target for autoimmune inflammatory diseases. *Immunology*. 2012; 135(2): 112-24. doi:10.1111/j.1365-2567.2011.03522.x
6. Tzimouli V, Trachana M, Taparkou A et al. The role of synovial fluid cytokines IL-6, IL-23 and IL-17 in the pathogenesis and persistence of synovial inflammation in JIA

- patients. *Pediatric Rheumatology*. 2008; 6(S1). doi:10.1186/1546-0096-6-s1-p12
7. McErlane F, Beresford MW, Baildam EM, et al. Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. *Ann Rheum Dis*. 2013;72(12): 1983-88. doi:10.1136/annrheumdis-2012-202031
 8. Sontichai, Watchareewan, and Soamarat Vilaiyuk. "The correlation between the Childhood Health Assessment Questionnaire and disease activity in juvenile idiopathic arthritis." *Musculoskeletal care*, 2018, vol. 16, 3: 339-44. doi:10.1002/msc.1239
 9. Bhalla A, Kaur H, Singh S. Auxological dynamics of children with Juvenile Idiopathic Arthritis: a mixed-longitudinal study from Chandigarh, North India. *Anthropologischer Anzeiger*. 2021; 78(4): 257-65. doi:10.1127/anthranz/2021/1314
 10. S. Prahalad, A. Whiting, B. Clifford, B. McNally, A. Zeft, J. Bohnsack. Serum and Synovial Fluid Concentrations of Interleukin-23 and Interleukin-17 in Juvenile Idiopathic Arthritis. Presentation at :*The American College of Rheumatology Annual Scientific meeting* ; 2007 ;Chicago, IL
 11. Szymańska-Kałuża J, Cebula-Obrzut B, Smolewski P, Stanczyk J, Smolewska E. Imbalance of Th17 and T-regulatory cells in peripheral blood and synovial fluid in treatment naïve children with juvenile idiopathic arthritis. *Central European Journal of Immunology*. 2014; 1: 71-6. doi:10.5114/ceji.2014.42128